Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
Under a Creative Commons license
open access
Abbreviations
Apo
apolipoprotein
BID
twice daily
CV
cardiovascular
CVD
cardiovascular disease
CE
cholesterol ester
CETP
cholesterol ester transfer protein
CRP
C-reactive protein
DAS28
Disease Activity Score with 28 joint-count
DMARD
disease-modifying antirheumatic drug
EULAR
European League Against Rheumatism
FC
free cholesterol
FCR
fractional catabolic rate
HDL
high-density lipoprotein
HDL-C
high-density lipoprotein cholesterol
JAK
Janus kinase
LCAT
lecithin–cholesterol acyltransferase
LDL
low-density lipoprotein
LDL-C
low-density lipoprotein cholesterol
LTE
long-term extension
MACE
major adverse cardiovascular event
MPO
myeloperoxidase
MTX
methotrexate
PON-1
paraoxonase-1
RA
rheumatoid arthritis
SAA
serum amyloid A
TC
total cholesterol
TCZ
tocilizumab
TG
triglyceride
TNF
tumor necrosis factor
Keywords
Disease-modifying antirheumatic drugs
Janus kinase
Rheumatoid arthritis
TNF inhibitors
Tofacitinib
Cited by (0)
© 2016 The Authors. Published by Elsevier Inc.